A new study has found that a common drug for diabetes can lower the risk of kidney failure. This particular finding has managed to raise the eyebrows of many, as diabetes is quite a major caused by kidney failure all over the world. The risk with regard to kidney failure and heart problems was on the lower side among patients with type 2 diabetes and kidney disease, who took a daily dose of canagliflozin. This was taken as part of the study that got published in a journal on Sunday.
Canagliflozin is used to reduce the risk of final stage kidney disease along with deaths due to heart or kidney problems in adults suffering from Type 2 diabetes and chronic kidney disease. The study included 4401 patients, who were aged 30 years and older, suffering from type 2 diabetes and chronic kidney disease. All those patients were assigned at 690 sites in a random manner in 34 countries to either take canagliflozin or even a placebo from March 2014 through May 2017. The researchers found out that canagliflozin reduced the risk of death from kidney problems by 34%. The risk of final stage kidney disease was lowered by 32%.
On the basis of this particular study, researchers felt that they could use canagliflozin only for benefits on a kidney. Plus, it could also carry certain heart benefits along with the use of other drugs to keep the glucose level among patients under control. It is especially applicable for those patients, who are suffering from kidney and diabetes disease. This particular trial was particularly designed to include certain individuals who had suffered from a diabetic renal problem and thus it becomes the first instance of getting the risk for kidney failures lowered and improving the outcomes of heart problems.
Charles has deep knowledge in the Health sector and that’s why he covers Health news for the website. Charles is very active on social media Charles is the go-to-guy for the publication and now contributes pieces for Times Slate for Health category on a regular basis.